ClevelandDx produce a next-generation diagnostic test for the early detection and monitoring of prostate cancer. IsoPSA®, is a blood‑based assay that helps physicians distinguish between elevated prostate‑specific antigen due to benign conditions vs high‑grade cancer, reducing unnecessary biopsies.